Oxal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxal

What is Oxal? An Overview

Property Description
Active Ingredient Ofloxacin
Form Oral tablet, Ophthalmic solution, Otic solution
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Treating bacterial infections
Origin Synthetic (chemically manufactured)

Oxal: A Synthetic Antibiotic and Fluoroquinolone Antimicrobial

Oxal is a prescription medicine defined by its active ingredient, Ofloxacin, which functions as a potent, broad-spectrum antibiotic used to manage bacterial infections. The drug is consistently classified within the fluoroquinolone antimicrobial family, a specific group of chemically synthesized agents. The active substance, Ofloxacin, is entirely synthetic, not naturally derived, and exists as a racemate—a mixture containing both the biologically active S-isomer (Levofloxacin) and the less active R-isomer. This chemical characteristic is clinically recognized in pharmacological literature, distinguishing its form from the isolated S-isomer often marketed separately.

What is the General Purpose of Ofloxacin?

The primary general purpose of the active ingredient Ofloxacin is to effectively eliminate illnesses caused by susceptible bacterial infections within the body. It achieves this through a bactericidal effect, meaning its mechanism is focused on directly killing the bacterial organisms. Ofloxacin exerts its action by interfering with the bacteria's vital processes, specifically by inhibiting essential enzymes, DNA gyrase and topoisomerase IV. This targeted disruption prevents the infectious agents from multiplying and allows the body to resolve the underlying problem, serving a general anti-infective purpose.

Oxal's Core Composition and Delivery Form

Oxal's composition centers on the single active pharmaceutical ingredient, Ofloxacin, which is complemented by inactive excipients suitable for its administration. The medication is prepared in distinct physical forms: the oral tablet for systemic treatment, and specialized solutions for localized application. This dual availability, including the oral route for treating systemic issues and the topical route for local infection management, allows healthcare providers the versatility to address both deep-seated and surface-level bacterial issues effectively.

What side effects are possible with Oxal?

Possible side effects and safety information

The fluoroquinolone antibiotic Ofloxacin (Oxal) is associated with documented adverse reactions and serious safety warnings, as classified by government regulatory authorities.


Classification of Officially Documented Adverse Reactions

Adverse reactions are classified by frequency and system organ class (SOC) in regulatory documents. Reactions commonly listed include those affecting the Gastrointestinal and Nervous System domains, such as nausea, diarrhea, headache, dizziness, insomnia, and restlessness.

Rare and serious adverse reactions are explicitly documented, often involving the musculoskeletal and nervous systems. These include Tendinitis and Tendon rupture (particularly of the Achilles tendon), which may occur rapidly or be delayed for months after discontinuing the medicine. Peripheral neuropathy (nerve damage) and serious Psychotic reactions are also reported CNS effects noted to be potentially long-lasting, disabling, or irreversible. Cardiac disorders like QT prolongation and Torsades de Pointes have been reported, primarily in at-risk patients.


Population-Specific and Contextual Safety Considerations

Official labeling highlights increased risks for specific populations. Older adults (over 60 years) and those taking corticosteroid drugs are identified as having a higher risk of tendon injury. The medicine is associated with a risk of blood glucose disturbances, including severe hypoglycemia, particularly in diabetic patients concurrently using anti-diabetic agents. Due to concerns regarding joint development, systemic use is generally contraindicated in the pediatric population. Use is restricted in patients with a history of tendon disorders related to this class of antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose profile for Oxal (Ofloxacin), based strictly on government regulatory sources (e.g., FDA, EMA SmPC).

Domain Official Regulatory Statements
Documented Overdose Presentations Overdose may involve gastrointestinal symptoms (nausea, vomiting) and Central Nervous System (CNS) effects, including drowsiness, dizziness, confusion, slurred speech, and facial numbness or swelling.
Life-Threatening Outcomes Severe consequences documented in regulatory information include the risk of convulsive seizures and cardiovascular effects such as QT interval prolongation.
Population-Specific Notes Patients with impaired renal function or severe hepatic dysfunction may face increased risk due to reduced clearance of the medicine.
Emergency-Response Statement If an acute oral overdose is suspected, the patient must contact a healthcare provider or nearest hospital casualty department immediately for assessment.
Classification Regulatory Context
Severity Classification Acute overdose is associated with the potential for severe and life-threatening outcomes, including seizures and cardiac rhythm abnormalities.
Overdose Management No specific antidote is known. Treatment is symptomatic and supportive, and may involve procedures such as gastric lavage or administration of activated charcoal to reduce absorption.

Resulting Overdose Structure

Official regulatory statements specify that immediate medical attention is required for the manifestation of severe symptoms, such as the onset of a seizure, or sudden abdominal, chest, or back pain indicative of potential aortic events. Due to the documented risk of QT prolongation, ECG monitoring is recommended in the management of an acute overdose. The official information is strictly descriptive, providing the basis for emergency response without offering therapeutic interpretation or general safety advice.

Therapeutic Uses of Oxal

What Oxal Treats: Main Uses and Benefits

Oxal, which contains ofloxacin, is used in situations involving certain distressing symptoms across several therapeutic domains. It is considered relevant in contexts involving heightened systemic burden, where supportive symptom management is appropriate. The medication is commonly used across conditions presenting with acute episodes, such as complicated urinary tract infections, chronic prostatitis, acute bacterial exacerbations of chronic bronchitis, and localized infections including conjunctivitis and otitis (ear infections). It helps address symptoms related to physical discomfort like painful urination (dysuria), acute cough, fever, and localized swelling.

Quick Fact: Symptomatic Support for Localized Discomfort

The medication supports both the addressing of systemic issues and localized symptomatic support for ear and eye infections, assists with maintaining functional stability.

“It is commonly used to help with groups of symptoms that appear suddenly, supporting the patient during difficult episodes by easing distress.”

Oxal is also applied in certain contexts for skin and soft tissue infections like cellulitis, and for supportive use in certain high-risk post-exposure contexts. Its application provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH DailyMed Ofloxacin Labeling

Eligibility and Restrictions for Use

The regulatory documents for 'Oxal' compounds (including Oxaliplatin, Escitalopram Oxalate, and Ofloxacin) establish clear eligibility criteria and contraindications.

Contraindicated Populations

Use is prohibited in individuals with a known hypersensitivity or allergy to the specific medicine or to its corresponding drug class (e.g., platinum-based drugs for Oxaliplatin, fluoroquinolones for Ofloxacin).

Additionally, specific clinical states strictly preclude use:

  • Drug-Drug Interactions: Concomitant use of Escitalopram Oxalate with Monoamine Oxidase Inhibitors (MAOIs) or pimozide is contraindicated.
  • Specific Conditions (Ofloxacin): Contraindicated in patients with a history of Myasthenia Gravis, tendon disorders (tendinitis/tendon rupture), or a history of seizures.
  • Organ Function (Oxaliplatin): Contraindicated in patients with severely impaired renal function (creatinine clearance less than 30 mL/min).

Age and Physiological Restrictions

  • Age-Related: Ofloxacin is not recommended for pediatric patients (generally under 18 years of age). For Escitalopram Oxalate, use in adolescents (12–17 years) is established for MDD, but safety in those under 12 is not established.
  • Pregnancy/Lactation: Use is generally prohibited or actively discouraged during breast-feeding (Oxaliplatin, Ofloxacin) and is subject to strict benefit-risk justification during pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oxal (Ofloxacin) has several formally documented interactions that affect its absorption, clearance, or result in additive pharmacodynamic risks, as detailed in regulatory labeling.

Contraindicated Combination

Category Substance Restriction
Prohibited Co-administration Fenbufen and similar NSAIDs Contraindicated in patients with a history of seizures.

Clinically Significant Interactions

Interaction Type Interacting Substances Regulatory Implication
Reduced Absorption Antacids (Aluminum, Magnesium), Sucralfate, Metal Cation Supplements (Iron, Zinc) Ofloxacin must be taken at least 2 hours before or 2 hours after these agents to prevent reduced serum concentration (chelation).
Altered Clearance Probenecid, Cimetidine Probenecid decreases Ofloxacin clearance by inhibiting renal tubular excretion, leading to increased exposure. Caution is advised for drugs affecting this pathway.
Potentiation of Effects Vitamin K Antagonists (e.g., Warfarin) Officially associated with reports of increased coagulation tests (PT/INR) and bleeding events.
Additive Risks Corticosteroids Increases the officially documented risk of tendon rupture, a risk noted as higher in elderly patients.
Cardiac Risk QT-prolonging drugs (e.g., Class IA/III Antiarrhythmics) Co-administration is a documented risk factor for QT interval prolongation.

Regulatory documentation establishes these constraints to mitigate risks related to chelation, increased drug exposure, or additive effects on the nervous system, heart, and musculoskeletal system.

Mechanism of Action

Molecular Mechanism: DNA Gyrase and Topoisomerase IV

Ofloxacin's action is defined by a bactericidal mechanism focused exclusively on the machinery that manages bacterial DNA, resulting in the direct destruction of the susceptible pathogen population. The molecule achieves its initial effect by targeting two enzymes essential for maintaining the bacterial genome's structure: DNA gyrase (a Type II topoisomerase) and topoisomerase IV. The drug acts as a trapping agent, binding to and stabilizing the cleavable complex—the intermediate state where the enzyme is attached to broken DNA strands. This binding prevents the enzymes from re-ligating the DNA, thereby trapping them on the bacterial chromosome.

Cellular Cascade and Constraints

The enzyme trapping initiates a lethal mechanistic cascade. When the bacterial cell attempts replication, the machinery collides with the trapped enzymes, converting the stabilized breaks into irreversible DNA double-strand breaks. This widespread genetic damage triggers the definitive bactericidal effect—the active killing of the bacterial cell—which results in the elimination of the susceptible bacterial population. The mechanism is constrained by bacterial counter-mechanisms, including genetic alterations in the target enzymes (e.g., gyrA and parC mutations) which reduce binding affinity, and the active transport of the drug out of the cell via efflux pumps.

Dosage and Administration Information

The usage of Oxal (Ofloxacin) is defined by its administration route, dosage structure, and prescribed duration. The medication is manufactured for two distinct routes: the oral tablet for systemic administration, and specialized 0.3% solutions for topical otic (ear) or ophthalmic (eye) application.

Oral dosing typically involves strengths ranging from 200 mg to 400 mg, administered at a twice-daily frequency (every 12 hours). The oral tablet is approved to be taken without regard to meals. For patients with reduced kidney function (renal impairment), the dose or frequency must be adjusted based on the measured creatinine clearance to maintain appropriate systemic exposure.

Topical administration requires specific procedural considerations. The otic solution must be warmed in the hand for one to two minutes prior to instillation to minimize the potential for dizziness. Furthermore, correct application often requires the ear to remain upward for a minimum of five minutes, and in certain ear conditions, the tragus must be pumped inward to aid penetration. Conversely, the otic solution is strictly constrained from being used in the eye, and the ophthalmic solution is constrained from being used in the ear.

The course duration is variable, ranging from a short 3-day regimen for certain infections to an extended six weeks for chronic conditions like prostatitis.

Recent Clinical Evidence

Research evidence / Overview of Studies for Oxal

Evidence for Use in Systemic Infections: Urinary Tract and Bronchitis

Research on Ofloxacin tablets for complicated urinary tract infections (cUTI) and acute bacterial exacerbations of chronic bronchitis (ABECB) has primarily involved short-term Randomized Controlled Trials (RCTs). These studies generally aimed to meet the research objective of non-inferiority, comparing Ofloxacin against established, active comparator treatments, rather than comparing it directly to a placebo or an inactive substance.

The studies were conducted in adults experiencing these acute conditions. Researchers monitored primary outcomes such as the Microbiological Eradication Rate and the Clinical Success Rate, which are measurements researchers used to evaluate the observed patterns at a designated check-up visit following the treatment period. The evidence contributes to understanding symptom patterns and describes the changes measured during the acute study phase.

Evidence for Use in Localized Ocular and Ear Infections

Evidence for the Ofloxacin solution (for eye and ear use) comes from controlled clinical trials that evaluated its use in localized conditions like bacterial conjunctivitis and corneal ulcers. These studies were often double-masked, providing a structured way to observe measured outcomes.

For conjunctivitis, research has explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort and objective measurements of clinical improvement. Findings describe patterns related to the specific conditions under which they were conducted, including measurements of microbiological clearance in the observed populations.

Current Research Gaps and Areas of Uncertainty

A key limitation noted by researchers is the frequent use of non-inferiority trials, which limits insight into the measured outcome when compared to a placebo. Additionally, key limitations include that the follow-up durations were limited in many pivotal trials, providing inadequate data on infection recurrence or functional long-term outcomes.

Evidence quality varies across studies, particularly for conditions affected by high rates of antibiotic resistance, leading to findings that were mixed or inconsistent in some regional reports. Scientific reviews note that data for certain groups (such as pregnant or breastfeeding populations) remain insufficient or limited.

Key Studies & References

  1. OCUFLOX® (ofloxacin ophthalmic solution) 0.3% sterile - U.S. Prescribing Information
  2. Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis
  3. Public Assessment Report Paediatric data EXOCIN (OCUFLOX) Ofloxacin Marketing Autorisation Holder: Allergan (Assessment of safety and efficacy in neonates)

Frequently Asked Questions (FAQ)

Common questions about Oxal (FAQ)

Q: What does the term 'contraindicated' mean when reading about Oxal?

The official product information uses the term 'contraindicated' to describe a condition or factor that strictly prevents the drug from being used. It means that using Oxal in a patient with that factor could potentially cause harm or significant risk. Regulatory documents list specific pre-existing conditions (such as a known allergy or history of certain disorders) that serve as a strong reason to withhold treatment with this medicine.

Q: What are the signs of a severe reaction to Oxal?

Regulatory documents warn that severe, yet rare, adverse reactions may occur. These signs include sudden, severe pain or swelling in a joint, signs of a tear like a snapping sound (tendon rupture), or severe, constant pain in the chest, stomach, or back (aortic damage). Other serious documented signs include severe changes in mood or behavior. If any of these are observed, contacting emergency medical services is an appropriate action.

Q: What types of over-the-counter medicines might interact with Oxal?

Official product information indicates that Oxal can interact with several types of over-the-counter products. It specifically warns against certain antacids and mineral supplements containing metal cations (like magnesium, iron, or zinc) because they can significantly reduce the absorption of the medicine. The use of certain non-steroidal anti-inflammatory drugs (NSAIDs) is also constrained due to a possible increased risk of seizures.

Q: Can Oxal be taken with common herbal supplements or vitamins?

Official guidance states that oral products containing metal cations (elements like iron, zinc, or magnesium) must be separated from Oxal by at least two hours. This is because these mineral components can bind to Oxal and prevent it from being fully absorbed. There is no specific official guidance found for all common herbal supplements, therefore, discussion regarding the use of specific supplements is generally advised.

Q: Is there an age limit for using Oxal, specifically for elderly patients?

Official documentation notes that older adults (those over 60 years of age) are identified as having a heightened risk of certain severe adverse reactions, particularly tendon injury. While no specific upper age limit is listed as a formal contraindication, this population is officially flagged for increased risk assessment.

Q: Is it necessary to avoid driving or operating machinery while using Oxal?

Official patient information advises that activities requiring mental alertness, such as driving or operating complex machinery, should be approached with caution until the effects of the medicine are understood. This is due to the potential for nervous system adverse effects such as dizziness or lightheadedness.

Q: What is the latest research finding about Oxal?

Studies supporting the use of Oxal typically involve Randomized Controlled Trials (RCTs) that focus on achieving non-inferiority compared to existing standard treatments. Researchers primarily monitor endpoints such as the Microbiological Eradication Rate (killing the bacteria) and the Clinical Success Rate (improving patient symptoms) over designated short study periods.

Q: How is Oxal eliminated from the body?

Official pharmacokinetic information states that the majority of the drug, about 65% to 80% of an oral dose, is excreted unchanged. This elimination occurs primarily through the kidneys via a process called renal tubular excretion. This is why dose adjustments are often necessary for patients with reduced kidney function.

Q: Is Oxal considered a controlled substance?

No, Ofloxacin is a prescription antibiotic, but official classifications do not list it as a controlled substance. According to regulatory bodies like the U.S. Drug Enforcement Administration (DEA), it is not scheduled.

Q: Is Oxal known by any other common brand or name?

Yes, the active ingredient in Oxal, which is Ofloxacin, has been marketed under several brand names throughout its use. These include the brand name Floxin for the systemic tablet form and Ocuflox for the ophthalmic (eye) solution.

Q: Is it normal to feel tired after starting Oxal?

The full list of officially documented adverse reactions for Ofloxacin includes reports of effects such as fatigue and somnolence (sleepiness). While these may not be among the most common adverse events, their documentation indicates they are known to occur.

Q: Do the common side effects of Oxal go away over time?

The official warnings emphasize that some serious nervous system adverse effects, such as peripheral neuropathy (nerve damage), are noted to be potentially long-lasting or irreversible after discontinuation. However, regulatory documents do not provide general guidance on the typical duration or resolution of common, mild side effects.

Q: Are there specific foods or drinks that interact with Oxal?

Official documentation states that the oral tablet may be taken without regard to meals, meaning it can be taken with or without food. No specific foods or beverages are listed as prohibited interactions in the regulatory labeling, though separation is required for metal-containing supplements.

Q: Does Oxal interact with common forms of birth control?

Some regulatory information suggests there is a low, theoretical risk that this class of antibiotics could decrease the effectiveness of oral contraceptives. This is thought to occur by altering the gut bacteria necessary for the recycling of hormones. This type of interaction should be discussed when reviewing medication use.

Q: How long does Oxal typically take to start working?

Pharmacokinetic studies show that the drug is rapidly absorbed into the bloodstream after an oral dose. Maximum concentration in the blood (Cmax) is typically achieved within one to two hours of taking the medicine.

Q: What is the expected time frame to see the full therapeutic effect of Oxal?

The time required to observe the full therapeutic effect varies significantly based on the type and severity of the infection being treated. In clinical trials, the efficacy (success rate) is generally measured at a designated check-up visit following the completion of the prescribed course of treatment.

Q: How long does Oxal usually stay in your system after stopping use?

Pharmacokinetic data indicates that Ofloxacin has an elimination half-life of approximately 9 hours. For most healthy individuals, the drug is considered to be fully eliminated from the body after about five times the half-life.

Q: If a dose of Oxal is missed, what is the general guidance on what to do?

Official patient information describes general guidance for missed doses. This guidance typically suggests taking the dose when remembered, unless the next dose is due shortly, in which case the missed dose is often omitted. It also advises against taking extra medicine to compensate for a missed dose.

Q: Where can I find official clinical trial data or research documents about Oxal?

Patients seeking detailed official information about the medicine, including full clinical trial summaries or regulatory labeling, are directed to authoritative governmental resources. These include the FDA website and the DailyMed database provided by the National Institutes of Health (NIH).

Q: Is Oxal a newly developed drug, or has it been available for a long time?

The active ingredient in Oxal, Ofloxacin, has been available for a long time. It received its initial approval from the U.S. Food and Drug Administration (FDA) in 1990.

Q: Is Oxal available in a generic version?

Yes, the active ingredient Ofloxacin is widely available in a generic version. The generic tablet is offered in various strengths by multiple manufacturers, as listed in regulatory databases like DailyMed.

Q: Is it true that Oxal can cause high blood pressure?

Official safety warnings do not list high blood pressure as a typical side effect caused by Oxal. However, regulatory documents identify patients with pre-existing conditions, including high blood pressure (hypertension), as being among those at potentially increased risk for a rare but serious adverse reaction concerning the aorta.

Q: What if I take too much Oxal by mistake?

If there is an accidental overdose, it is advised to treat the situation as an emergency. In situations of accidental overdose, contacting emergency medical services or the Poison Help line is the appropriate action to seek guidance.

How should Oxal be stored and disposed of?

Storage and Handling Requirements

Oxal (Ofloxacin) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. Official labeling requires the product to be kept in its original closed container, away from direct light, heat, and moisture, and it must be kept from freezing. As a safety precaution, the medicine should be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Ofloxacin must be disposed of according to local governmental regulations. Patients are often advised to utilize drug take-back programs at authorized locations. The product should not be kept past its expiration date, and disposal instructions generally require that the medicine not be released into the environment or poured down drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxal found in:

A-Z Index: